| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/22/2003 | US6551626 Composition containing pyrrolizidine-alkaloid-free petasites |
| 04/22/2003 | US6551622 Storage-stable hydrophilic therapeutic agent is prepared by formulating therapeutic proteins with hydrophobically-derivatised carbohydrates; drug delivery |
| 04/22/2003 | US6551621 A protective coatings for improving drug stability over time; treatment of gastric and duodenal ulcers |
| 04/22/2003 | US6551620 Pellet formulation for the treatment of the intestinal tract |
| 04/22/2003 | US6551619 Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation |
| 04/22/2003 | US6551617 Taste masking coating composition |
| 04/22/2003 | US6551616 Reducing gastrointestinal adverse side effects and improving taste |
| 04/22/2003 | US6551615 Capsule containing dexibuprofen (ibuprofen) dissolved in a solubilizer, a potassium salt forming compound, surfactants, co-surfactants, and a viscosity imparter; bioavailability |
| 04/22/2003 | US6551613 Dosage form comprising therapeutic formulation |
| 04/22/2003 | US6551611 Hormone replacement therapy method |
| 04/22/2003 | US6551610 Multifaceted compositions for post-surgical adhesion prevention |
| 04/22/2003 | US6551607 Method for sequestration of skin irritants with substrate compositions |
| 04/22/2003 | US6551605 Diesters or polyesters of naphthalene dicarboxylic acid as solubilizer/stabilizer for retinoids |
| 04/22/2003 | US6551601 Fatty acids, mono and/or di-glycerides of fatty acids, and polyethoxylated fatty acid esters in given weight % with nonpolar lipids, fatty alcohols, lipophilic bodying agents of given melting point, hydrogenated polyisobutylene and polar |
| 04/22/2003 | US6551590 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 04/22/2003 | US6551584 Topical antibiotic composition for treatment of eye infection |
| 04/22/2003 | US6551579 Delivery systems for a tooth whitener |
| 04/22/2003 | US6551578 Stability, aerosols, drug delivery; therapy |
| 04/22/2003 | US6551577 Topical spray for burn treatment and anti-infection |
| 04/22/2003 | US6551576 Container with multi-phase composition for use in diagnostic and therapeutic applications |
| 04/22/2003 | US6551532 Method and device for forming particles |
| 04/22/2003 | US6551353 Synthetic fibers for medical use and method of making the same |
| 04/22/2003 | US6551276 External infusion device with remote programming bolus estimator and/or vibration alarm capabilities |
| 04/22/2003 | US6550955 Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface |
| 04/22/2003 | US6550474 Microencapsulated fragrances and methods of coating microcapsules |
| 04/22/2003 | CA2304784C A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof |
| 04/22/2003 | CA2292673C Pharmaceutical compositions containing eletriptan hemisulphate |
| 04/22/2003 | CA2264960C External formulation containing loxoprofen |
| 04/22/2003 | CA2235243C Method and preparations for stabilizing biological materials by drying methods without freezing |
| 04/22/2003 | CA2132012C Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| 04/22/2003 | CA2061520C Delivery system for enhanced onset and increased potency |
| 04/22/2003 | CA2027833C Implant material, method for the manufacture thereof and procedure for the application of the material |
| 04/19/2003 | CA2361882A1 Liquid for oral administration comprising paroxetine |
| 04/17/2003 | WO2003031593A2 MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES |
| 04/17/2003 | WO2003031477A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 04/17/2003 | WO2003030984A1 Microdevice and method of delivering or withdrawing a substance through the skin of an animal |
| 04/17/2003 | WO2003030953A1 Inhibition of exoprotein production using aromatic compositions |
| 04/17/2003 | WO2003030943A1 Compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
| 04/17/2003 | WO2003030942A1 Pharmaceutical formulation |
| 04/17/2003 | WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | WO2003030939A1 Therapies for treating respiratory diseases |
| 04/17/2003 | WO2003030935A2 Adjuvants for nucleic acid vaccines |
| 04/17/2003 | WO2003030923A1 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
| 04/17/2003 | WO2003030921A1 Methods for producing agrimonia extract with improved activity against hepatitis B virus and pharmaceutical and food compositions containing said extract |
| 04/17/2003 | WO2003030920A1 An antispasmodic agent spaced drug delivery system |
| 04/17/2003 | WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 04/17/2003 | WO2003030913A2 Use of dendrimers in an ophthalmic composition |
| 04/17/2003 | WO2003030906A1 Treating infections by administration of oxazolidinones to the skin |
| 04/17/2003 | WO2003030896A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 04/17/2003 | WO2003030883A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 04/17/2003 | WO2003030882A1 Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform |
| 04/17/2003 | WO2003030881A1 Glucan based film delivery systems |
| 04/17/2003 | WO2003030880A1 Transdermal delivery devices |
| 04/17/2003 | WO2003030879A1 Particle immobilized coatings and uses thereof |
| 04/17/2003 | WO2003030878A2 Galenic microparticulate oral formulation |
| 04/17/2003 | WO2003030877A1 Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 04/17/2003 | WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | WO2003030875A1 Over-coated chewing gum formulations including tableted center |
| 04/17/2003 | WO2003030874A1 Pharmaceutical composition for releasing an active substance at the colon |
| 04/17/2003 | WO2003030873A1 Therapeutic biological product and method for formation of new vascularised bone |
| 04/17/2003 | WO2003030872A2 Compositions having a combination of particles for immediate release and for controlled release |
| 04/17/2003 | WO2003030871A1 Powder processing with pressurized gaseous fluids |
| 04/17/2003 | WO2003030870A1 Prolonged release biodegradable microspheres and method for preparing same |
| 04/17/2003 | WO2003030869A1 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
| 04/17/2003 | WO2003030868A1 Flashmelt oral dosage formulation |
| 04/17/2003 | WO2003030867A2 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid |
| 04/17/2003 | WO2003030866A1 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides |
| 04/17/2003 | WO2003030865A1 Pro-micelle pharmaceutical compositions |
| 04/17/2003 | WO2003030864A1 Liposomal formulation of irinotecan |
| 04/17/2003 | WO2003030863A1 Tablet delivery system |
| 04/17/2003 | WO2003030862A2 Anaesthetic compositions and method for their administration |
| 04/17/2003 | WO2003030829A2 Liposome-encapsulated insulin formulations |
| 04/17/2003 | WO2003030818A2 Active agents using liposome beads |
| 04/17/2003 | WO2003030793A1 Hydrating nasal gel and applicator |
| 04/17/2003 | WO2003017927A3 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 04/17/2003 | WO2003008026A3 Apparatus for self-induced cough-cardiopulmonary resuscitation |
| 04/17/2003 | WO2003007922A3 Pharmaceutical formulation containing an ltb4 antagonist |
| 04/17/2003 | WO2003002156A3 Contrast agents comprising metal particles encapsulated in microspheres for use in medical diagnostic imaging and therapy |
| 04/17/2003 | WO2002089770A3 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine |
| 04/17/2003 | WO2002083700A3 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 04/17/2003 | WO2002078728A3 Peptides for the treatment of wound contracture |
| 04/17/2003 | WO2002076426A3 Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| 04/17/2003 | WO2002076392A3 Thermally reversible water in oil in water emulsions |
| 04/17/2003 | WO2002072636A3 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/17/2003 | WO2002067895A3 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
| 04/17/2003 | WO2002058718A3 Use of compositions containing pdgf-bb for promoting angiogenesis |
| 04/17/2003 | WO2002058684A3 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 04/17/2003 | WO2002051237A9 Helicobacter proteins, nucleic acids and uses thereof |
| 04/17/2003 | WO2002047704A9 Herbal pharmaceutical compositions for treating immunological disorders |
| 04/17/2003 | WO2002041871A3 Composition comprising an imexon or derivatives thereof and lipids |
| 04/17/2003 | WO2002034206A9 Felodipine transdermal device and methods |
| 04/17/2003 | WO2002024891A3 B7-like molecules and uses thereof |
| 04/17/2003 | WO2002024173A3 Oral dosage forms of boswellia extracts |
| 04/17/2003 | WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 04/17/2003 | WO2002017881A3 Transdermal pharmaceutical delivery composition |
| 04/17/2003 | WO2001089494A8 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 04/17/2003 | WO1999056766A3 Method for treating ischemia |
| 04/17/2003 | US20030074024 System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
| 04/17/2003 | US20030073979 Medical device for delivering patches |
| 04/17/2003 | US20030073952 Laminated patient infusion device |